Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
64 hedge funds and large institutions have $244M invested in Cymabay Therapeutics in 2017 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 22 increasing their positions, 6 reducing their positions, and 10 closing their positions.
275% more capital invested
Capital invested by funds: $65M → $244M (+$179M)
267% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 6
250% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 10
219% more call options, than puts
Call options by funds: $402K | Put options by funds: $126K
64% more funds holding
Funds holding: 39 → 64 (+25)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$15.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$15.7M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$11.5M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$11.1M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$10.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
-$3.74M |
| 2 |
JGC
J. Goldman & Co
New York
|
-$1.73M |
| 3 |
A
Abingworth
London,
United Kingdom
|
-$387K |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$242K |
| 5 |
ACI
Alpha Cubed Investments
Irvine,
California
|
-$115K |
CBAY Hedge Fund Activity: Q3 2017 in Review
64 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q3 2017, worth a combined $244M — up 275% from $65M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new CBAY positions and 10 closed out — a net gain of 25 holders — while 22 added to existing stakes and 6 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $15.9M. The largest seller was Ghost Tree Capital, exiting entirely with an estimated $3.74M sold.
- 64 institutional investors held Cymabay Therapeutics (CBAY) as of Q3 2017, up from 39 in Q2 2017.
- Funds reported $244M of Cymabay Therapeutics stock for Q3 2017, up 275% quarter-over-quarter.
- 35 funds opened new Cymabay Therapeutics positions in Q3 2017 and 10 closed out, a net change of +25 holders.
- The largest Cymabay Therapeutics buyer in Q3 2017 was Perceptive Advisors, an estimated $15.9M added.
- The largest Cymabay Therapeutics seller in Q3 2017 was Ghost Tree Capital, an estimated $3.74M sold.
Based on aggregated 13F filings for Q3 2017.